Boehringer Ingelheim and Epizyme Announce Global Collaboration to Develop New Epigenetic Therapies in Oncology
[ad_1] CAMBRIDGE, Massachusetts and INGELHEIM, Germany – (COMMERCIAL THREAD) – Boehringer Ingelheim and Epizyme, Inc. (Nasdaq: EPZM) today announced a new global collaboration focused on the research, development and commercialization of novel small molecule inhibitors directed at two previously untreated epigenetic targets as potential therapies for people with cancer. More specifically, these targets are enzymes […]